Oncotarget

Meta-Analysis:

Meta-analysis of the prognostic value of p-4EBP1 in human malignancies

Tao Zhang, Jianrong Guo, Huili Li _ and Jiliang Wang

PDF  |  HTML  |  Supplementary Files  |  How to cite  |  Order a Reprint

Oncotarget. 2018; 9:2761-2769. https://doi.org/10.18632/oncotarget.23031

Metrics: PDF 380 views  |   HTML 728 views  |   ?  


Abstract

Tao Zhang1, Jianrong Guo1, Huili Li1 and Jiliang Wang1

1Department of Gastrointestinal Surgery, Union Hospital, Tongji Medical College, Huazhong University of Science and Technology, Wuhan, 430022, Hubei, China

Correspondence to:

Huili Li, email: huili_li@hust.edu.cn

Jiliang Wang, email: jiliang_wang@hust.edu.cn

Keywords: p-4EBP1; prognosis; cancer; meta-analysis; malignancies

Received: July 02, 2017     Accepted: September 20, 2017     Published: December 07, 2017

ABSTRACT

Phosphorylated 4E-binding protein 1 (p-4EBP1) is the inactivated form of 4EBP1, which is a downstream mediator in the mTOR signaling pathway and a vital factor in the synthesis of some oncogenic proteins. This meta-analysis was conducted to assess the predicative value of p-4EBP1 expression in human malignancies. The PubMed and Embase databases were carefully searched. Articles comparing the prognostic worthiness of different p-4EBP1 levels in human malignancies were collected for pooled analyses and methodologically appraised using the Newcastle-Ottawa Scale (NOS). A total of 39 retrospective cohorts with an overall sample size of 3,980 were selected. Patients with lower p-4EBP1 expression had better 3-year (P < 0.00001), 5-year (P < 0.00001), and 10-year (P = 0.03) overall survival and better 3-year (P < 0.0001) and 5-year (P = 0.0005) disease-free survival. Subgroup analyses confirmed the unfavorable prognosis associated with p-4EBP1 overexpression. These findings were further validated by sensitivity analyses. Harbord and Peters tests revealed no publication bias within the included studies. It thus appears higher expression of p-4EBP1 indicates a poor prognosis in human malignancies.


Creative Commons License All site content, except where otherwise noted, is licensed under a Creative Commons Attribution 3.0 License.
PII: 23031